Benzinga's M&A Chatter for Monday June 10, 2013

The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday June 10, 2013:

:

reported Monday that Elan

might be willing to a cash offer of $15.50 per share from Royalty Pharma. Earlier, Elan announced that its Board of Directors has rejected the bid $13.00 plus up to $2.50 per share in contingent value rights. Later, Elan announced withdrawal of its complaint against Royalty Pharma, who was forced to revise its tender offer documents to provide significant amounts of additional information in revised tender offer documents filed by Royalty Pharma with the US Securities and Exchange Commission late Friday afternoon. Elan Corporation closed at $13.62 Monday, a gain of 1% on almost 3 times average volume.

:

Google

is close to a deal to acquire Israeli social mapping service Waze for $1.3B, according to

. A spokesperson for Google declined comment on the report. A Waze spokesperson was not available for comment. Google closed at $890.22 Monday, a gain of 1% on average volume.

:

Shares of Fusion-io

moved higher in early trading on Monday on renewed chatter of a potential offer from IBM

. The buyout price was mentioned as $23 per share. Spokespersons for IBM and Fusion-io declined comment on the rumor. Fusion-io closed at $14.25 Monday, a gain of 1.71% on average volume.

:

AstraZeneca

announced Monday that it has agreed to acquire Pearl Therapeutics for $560 million payable on completion of the deal. Additional milestone payments of up to $450 and sales related payments of up to $140 million would bring the potential total to $1.15 billion. The deal is expected to close in Q3 of 2013. AstraZeneca closed at $51.40 Monday, a loss of $0.05 on average volume.